

<b>NCT ID</b>	NCT04014530
<b>Title</b>	Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-07-10
<b>Location</b>	Netherlands
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Ataluren + Pembrolizumab, Keytruda
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT04009681
<b>Title</b>	A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2019-07-05
<b>Location</b>	Arizona, United States Colorado, United States Florida, United States Tennessee, United States Texas, United States Argentina Australia Chile Singapore Spain
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Terminated
<b>Drugs</b>	anti-EGFR antibody, Checkpoint inhibitor, THOR-707
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT04008030
<b>Title</b>	A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW )
<b>Phase</b>	Phase 3
<b>Date Added</b>	2019-07-05

<b>Location</b>	California, United States Colorado, United States Illinois, United States New York, United States Oregon, United States Pennsylvania, United States Texas, United States Virginia, United States Argentina Australia Austria Belgium Brazil Canada Chile China Czechia Denmark France Germany Greece Ireland Italy Japan Netherlands Norway Puerto Rico Romania Spain Turkey (Türkiye) United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Bevacizumab, cetuximab, fluorouracil, Irinotecan, Leucovorin, oxaliplatin
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT04003792
<b>Title</b>	Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.
<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-07-01
<b>Location</b>	Israel
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Bevacizumab, FOLFIRI Protocol, oxaliplatin
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03994601
<b>Title</b>	An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-06-21

<b>Location</b>	California, United States Colorado, United States Maryland, United States Missouri, United States New Jersey, United States Argentina Canada Chile France Italy Spain
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	BMS-986288, Nivolumab, Opdivo
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03990233
<b>Title</b>	A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-06-18
<b>Location</b>	Belgium France
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Completed
<b>Drugs</b>	BI 754091, BI 765063
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03985891
<b>Title</b>	The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
<b>Phase</b>	Phase 1/Phase 2
<b>Date Added</b>	2019-06-14
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03984578
<b>Title</b>	Window of Opportunity Study in Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-06-13
<b>Location</b>	Singapore
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Completed
<b>Drugs</b>	Capecitabine/ 5-FU, CapeOX, Pembrolizumab, Eloxatin, Keytruda
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03983993
<b>Title</b>	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer

<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-06-12
<b>Location</b>	Georgia, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Niraparib, panitumumab, Vectibix, Zejula
<b>Tags</b>	MSS/ MMRp

---

<b>NCT ID</b>	NCT03981146
<b>Title</b>	A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-06-10
<b>Location</b>	United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Nivolumab, Opdivo
<b>Tags</b>	MSS/ MMRp